Market Place
Sourcing Support
Cara Therapeutics and Tvardi Enter Merger Agreement
18 Dec 2024 //
GLOBENEWSWIRE
Tvardi To Present TTI-101 Data For IPF Trial At CHEST 2024
02 Oct 2024 //
BUSINESSWIRE
Tvardi Therapeutics to Present at the 8th Annual IPF Summit
14 Aug 2024 //
BUSINESSWIRE
Tvardi Therapeutics To Participate In BTIG Biotech Conference
31 Jul 2024 //
BUSINESSWIRE
Tvardi Therapeutics Appoints Sujal Shah as Chairman
26 Mar 2024 //
BUSINESSWIRE
Tvardi to Participate at the Cowen 44th Annual Health Care Conference
01 Mar 2024 //
BUSINESSWIRE
Tvardi Announces Presentation of REVERT LIVER CANCER Phase 2 Trial Using TTI-101
18 Jan 2024 //
BUSINESSWIRE
Tvardi to Present at the 35th Annual Piper Sandler Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Tvardi Announces First Patients Dosed in its Ph2 IPF Trial using TTI-101
31 Aug 2023 //
BUSINESSWIRE
Tvardi doses first patients in REVERT Liver Cancer trial
23 Jun 2023 //
CLINICAL TRIALS ARENA
Tvardi Announces First Patients Dosed its Ph2 Liver Cancer Trial Using TTI-101
22 Jun 2023 //
BUSINESSWIRE
Tvardi Announces Presentation of Data from the Phase 1 Trial of TTI-101
25 May 2023 //
BUSINESSWIRE
Tvardi to Participate at the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
BUSINESSWIRE
Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101
23 Feb 2023 //
BUSINESSWIRE
Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer
07 Feb 2023 //
BUSINESSWIRE
Tvardi Therapeutics to Present at the Guggenheim Securities Oncology Conference
03 Feb 2023 //
BUSINESSWIRE
Tvardi to Participate at the SVB Securities Global Biopharma Conference
31 Jan 2023 //
BUSINESSWIRE
Tvardi to Present at the 34th Annual Piper Sandler Healthcare Conference
29 Nov 2022 //
BUSINESSWIRE
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101
19 Oct 2022 //
BUSINESSWIRE
Tvardi to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
08 Sep 2022 //
BUSINESSWIRE
Tvardi Therapeutics’ TTI-101 Receives ODD for Idiopathic Pulmonary Fibrosis
26 May 2022 //
BUSINESSWIRE
Tvardi Therapeutics to Participate in Morgan Stanley Private Company
28 Apr 2022 //
BUSINESSWIRE
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation
21 Apr 2022 //
BIOSPACE
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular
21 Apr 2022 //
BUSINESSWIRE
Biotech incubator Sporos` new CEO arrives from Ovid
29 Sep 2021 //
FIERCEBIOTECH
Tvardi Therapeutics Raises $74 Million in Series B Financing
23 Jun 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.